INS and early-onset autosomal dominant Alzheimer disease: In the prespecified analyses, intranasal insulin treatment using another device was associated with better cognitive function than placebo on the Alzheimer Disease Assessment Scale–Cognitive test (ADAS-Cog12) at 6 months, which strengthened after 18 months of treatment [62].